Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIDA long-term safety extension study of ontamalimab in ulcerative colitis and Crohn's disease
2017-000574-11Phase 3Completed
- Sponsor
- Takeda
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ontamalimab in autoimmune colitis and Crohn's disease, sponsored by Takeda. Primary endpoint: Primary safety endpoint. Started Sep 2017; status: completed.
02
Drugs
ontamalimab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on 2017-000574-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000574-11.